FdaApplication
NDA 208855
Identifiers
- fda_app_no: NDA208855
Properties
| Property | Value |
|---|---|
| applicant_name | ELI LILLY AND CO |
| application_type | NDA |
Revenue by product
VERZENIO
| Period | Revenue |
|---|---|
| Q2 2026 | $1.5B |
| Q1 2026 | $1.3B |
| Q4 2025 | $1.6B |
| Q3 2025 | $1.5B |
| Q2 2025 | $1.5B |
| Q1 2025 | $1.2B |
| Q4 2024 | $3.1B |
| Q3 2024 | $2.7B |
| Q2 2024 | $2.7B |
| Q1 2024 | $2.1B |
| Q4 2023 | $1.1B |
| Q3 2023 | $1.0B |
| Q2 2023 | $926.8M |
| Q1 2023 | $750.9M |
| Q4 2022 | $807.9M |
| Q3 2022 | $617.7M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (4)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VERZENIO | ABEMACICLIB | 200MG | TABLET;ORAL |
| VERZENIO | ABEMACICLIB | 150MG | TABLET;ORAL |
| VERZENIO | ABEMACICLIB | 50MG | TABLET;ORAL |
| VERZENIO | ABEMACICLIB | 100MG | TABLET;ORAL |
4 products